Mumbai, India

Kalindi Gandhi

This inventor holds 1 USPTO granted patent. Top assignee: Cipla Limited. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kalindi Gandhi. Retrieved from https://idiyas.com/inventor/kalindi-gandhi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kalindi Gandhi: Innovator in Intranasal Formulations

Introduction

Kalindi Gandhi is a notable inventor based in Mumbai, India. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of intranasal delivery systems.

Latest Patents

Kalindi Gandhi holds a patent for an intranasal formulation of midazolam. This invention relates to a new formulation that allows for the administration of midazolam through the nasal route. The formulation contains midazolam in a high concentration, ranging from about 1% to about 10% w/w, and includes a detailed process for its preparation.

Career Highlights

Kalindi Gandhi is currently associated with Cipla Limited, a leading global pharmaceutical company. His work focuses on innovative drug delivery systems that enhance the efficacy and convenience of medication administration.

Collaborations

Some of his coworkers include Geena Malhotra and Sarabjit Singh, who contribute to the collaborative efforts in research and development at Cipla Limited.

Conclusion

Kalindi Gandhi's work in intranasal formulations exemplifies the innovative spirit in the pharmaceutical industry. His contributions are paving the way for more effective drug delivery methods.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…